Evaluation of the Interest to Combine a CD4 Th1-inducer Cancer Vaccine Derived From Telomerase and Atezolizumab Plus Bevacizumab in Unresectable Hepatocellular Carcinoma

This study is testing a combination of an experimental cancer vaccine (designed to activate immune cells against a protein called telomerase, which is active in many cancer cells) along with two standard immunotherapy drugs — atezolizumab and bevacizumab — in people with advanced liver cancer (hepatocellular carcinoma, or HCC) that cannot be surgically removed. **You may be eligible if...** - You are 18 or older with confirmed, unresectable advanced or metastatic liver cancer - You have not previously received systemic (whole-body) anti-cancer therapy - You have measurable disease and adequate liver function (Child-Pugh Class A) - Your cancer is at BCLC stage B (not eligible for local treatment) or stage C - You are in good physical condition (performance status below 2) **You may NOT be eligible if...** - You have previously received immunotherapy (anti-PD-1, anti-PD-L1, anti-CTLA-4, or any immune therapy) - You have been diagnosed with another cancer within the last 3 years (other than treated basal cell skin cancer or in-situ cervical/breast cancer) - You have a serious medical or psychiatric condition that would interfere with treatment Talk to your doctor to see if this trial is right for you.